Novo Nordisk has ballooned to become one of Europe’s most valuable companies, thanks to skyrocketing sales of Ozempic, the diabetes medicine that’s grown into a world—leading weight-loss drug.
Our waistlines have also ballooned—and not just from the excesses of the festive period. Novo Nordisk estimates there are 1 billion people worldwide suffering from obesity, and already an estimated 8 million people are trusting next-generation weight-loss drugs like Ozempic to shed those extra pounds.
